FR2835527A1 - SYNTHESIS OF GLYCAN INOSITOLPHOSPHATE-LIKE MOLECULES: TREATMENT OF CELL PROLIFERATION AND METABOLIC DISORDERS CHARACTERIZED BY INSULIN RESISTANCE - Google Patents

Abstract

The invention relates to compounds of formula A related to glycan inositolphosphates, their use as a medicament, in particular for the treatment of diseases associated with deficient glucose metabolism, and for the treatment of diseases associated with excessive cell proliferation:

Description

<Desc / Clms Page number 1>

The invention relates to compounds related to glycan inositolphosphates, their use as a medicament, in particular for the treatment of diseases associated with impaired glucose metabolism, and for the treatment of diseases associated with excessive cell proliferation.

Among the diseases associated with a deficient glucose metabolism, diabetes is particularly targeted. According to the mechanism in question, the WHO classification distinguishes insulin-dependent diabetes (IDD), requiring daily administration of insulin and which corresponds overall to juvenile or type 1 diabetes, and non-insulin-dependent diabetes (DNID) which corresponds with late onset or type 2 diabetes. According to the results of the CODE 2 study (Costs of Diabetes in Europe, type 2) published in 1999, the 10 million type 2 diabetics from the eight European countries studied represent an expenditure corresponding on average to 5% of health expenditure. In the United States, this pathology represents the fourth cause of death and the expenses related to this disease are considerable.

The estimated progression of diabetes is worrying, 120 million type 2 diabetics in the world today, 150 million in the year 2005,213 million in 2010.

In France, the prevalence of type 2 diabetes in the general population is estimated at around 2%, or 1.2 million people affected.

It is therefore important to study the mechanisms of action of insulin, to synthesize new insulin-mimetic molecules to increase the choice of prescribers and best customize the treatment according to the type of diabetes. The regulation of glucose metabolism by insulin involves various hormones with antagonistic effects, receptors, messengers, glucose transporters, enzymes and their substrates. The alteration of one of the links in the complex regulatory chain is capable of disrupting the entire system.

glycosylphosphatidylinositols (GPI) libres ou ancrant des protéines. Les GPI sont constitués d'inositol, de glucosamine non-N-acétylée, de glucides et d'acides gras The action of a large number of hormones and growth factors has been shown to be mediated in part by second messengers belonging to the family of glycan inositolphosphates (IPG). In particular, in subjects with type 2 diabetes, an alteration in the metabolism of glycan inositolphosphates is frequently observed. IPGs originate from

glycosylphosphatidylinositols (GPI) free or protein-anchoring. GPIs consist of inositol, non-N-acetylated glucosamine, carbohydrates and fatty acids

<Desc / Clms Page number 2>

 saturated. Numerous studies have focused on the search for molecules of the IPG family with hypoglycemic properties.

l'interleukine-2 (IL-2), l'érythropoïétine (EPO) ou le"transforming growth factor-ssl" (TGF-Bl) contrôlaient la libération d'IPG après hydrolyse d'un GPI par une phospholipase spécifique (Varela-Nieto et al. (1996) Comp. Biochem. Physio. ll5B, 223-241 ; Bogdanowicz al. (2001) Mci 17, 577-585). In terms of the mechanism of action of such mediators, it has been shown that, in various cell types, insulin, the "nerve growth factor" (NGF),

interleukin-2 (IL-2), erythropoietin (EPO) or "transforming growth factor-ssl" (TGF-B1) controlled the release of IPG after hydrolysis of a GPI by a specific phospholipase (Varela- Nieto et al. (1996) Comp. Biochem. Physio. 115B, 223-241; Bogdanowicz al. (2001) Mci 17, 577-585).

mimer l'action de l'insuline (Saltiel et al. (1986) Proc. Nat. Acad Sei 83, 5793-5797). Depuis, des travaux complémentaires ont montré que ces composés étaient constitués de glucides, de glucosamine non N-acétylée, d'inositol et d'un nombre variable de phosphates. Deux types d'IPG impliqués dans les mécanismes de transduction de l'insuline ont pu être isolés. Le myo-IPG, également appelé IPG de type A, est constitué de myo-inositol et de glucosamine. Cette isoforme a un effet négatif sur l'activité des protéine-kinases dépendantes de l'AMPc en inhibant l'adénylate cyclase et en activant l'AMPc phosphodiestérase. Dans les adipocytes de rat, elle augmente la lipogénèse via l'activation de l'acétylCoA carboxylase. Le chiro-IPG, ou forme P, est constitué de chiro-inositol méthylé, également appelé pinitol, et de galactosamine. However, although there are data concerning the composition of these mediators, their precise structure is still poorly understood, and minor variations in their composition seem to be at the origin of the diversity of their biological activity observed in many cell types. . In 1986, Saltiel and Cuatrecasas isolated two substances from liver plasma membranes. These two substances, with a molecular weight of around 1000 to 2000 Da, were capable of

mimic the action of insulin (Saltiel et al. (1986) Proc. Nat. Acad Sci 83, 5793-5797). Since then, additional work has shown that these compounds consist of carbohydrates, non-N-acetylated glucosamine, inositol and a variable number of phosphates. Two types of IPG involved in the mechanisms of insulin transduction could be isolated. Myo-IPG, also called IPG type A, consists of myo-inositol and glucosamine. This isoform has a negative effect on the activity of cAMP-dependent protein kinases by inhibiting adenylate cyclase and activating cAMP phosphodiesterase. In rat adipocytes, it increases lipogenesis via the activation of acetylCoA carboxylase. Chiro-IPG, or form P, consists of methylated chiro-inositol, also called pinitol, and galactosamine.

By stimulating the activity of glycogen synthetase phosphatase, this isoform increases the level of glycogen synthesis. It also activates pyruvated dehydrogenase phosphatase, but has no effect either on lipid metabolism or on the activity of cAMP-dependent protein kinases (US Patent No 4,446,064; Lamer et al (1988) Biochem. Biophys. Res. Comm. 151,1416-1426).

The numerous researches carried out led to a large number of compounds intended to have an insulinomimetic action, described in particular in the following documents.

<Desc / Clms Page number 3>

 WO99 / 06421 describes amino disaccharide compounds involving a slightly modified inositol.

Patent AU 5 116 496 describes IPG compounds purified from living organisms (Trypanosome and bovine liver), but this technique does not make it possible to know the composition and the exact structure of IPGs; moreover, the risk of possible contamination by pathogenic agents is far from negligible.

The document Biochemistry, 1998, vol 37.38, 13421-13436 describes synthetic IPGs comprising a basic motif constituted by a skeleton of three mannose residues, and specifies that an inositol group including the mannose side chain in the appropriate glycosidic binding position. is necessary for insulin-like activity. Furthermore, this document dissuades a person skilled in the art from using phosphodissacharides which he describes as clearly less effective.

US Pat. No. 6,004,938 describes compounds of the IPG type, in particular of the pentasaccharide type, obtained by chemical synthesis, effective, but the synthesis of which is very complex requiring up to fifty synthesis steps.

Thus, the known compounds do not meet all the desired criteria of efficiency, ease of synthesis, safety.

 Regarding diseases associated with excessive cell proliferation, it is known that the signaling pathway involving IPG intervenes in the mechanism of action of many cytokines, hormones or growth factors, in particular TGF-B. This growth factor intervenes in particular in the healing processes, in the formation of the extracellular matrix or the control of the cell cycle. It acts via two receptors with serine / threonine kinase activity, called type 1 and II (TssR-I and TssR-II). Cells lacking these receptors or expressing a mutated form of these receptors become resistant to the effects of TGF-ss, as is the case in non-polyposic colorectal cancers, certain cancers of the pancreas, prostate, kidney, certain metastatic lung cancers or chronic lymphoid leukemias ....

The binding of TGF-ss to its receptors allows the recruitment of cytoplasmic proteins of the Smad family which play a central role both in controlling cell proliferation and in the transcriptional activity of genes of matrix molecules.

<Desc / Clms Page number 4>

 In addition to these mechanisms, the inventors have demonstrated that TGF-B stimulates the production of IPG in an epithelial cell line (Mv; Lu), in which it induces an inhibition of proliferation. This IPG, the precise structure of which is not known, contains inositol, phosphate and glucosamine. This IPG, now known to those skilled in the art, is capable of mimicking the effects of TGF-ss on the inhibition of DNA synthesis. This antiproliferative effect is exerted independently of the presence of the type 1 receptor. In fact, the IPG inhibits the proliferation of the R-IB sub-line which is a mutant of Hake not expressing the functional TssR-I receptor. The IPG therefore acts on one or more targets, downstream of the receptors. These results indicate that the release of IPG is an important step in the control of cell proliferation by TGF-ss. Furthermore, the fact that cells resistant to the antiproliferative effects of TGF-ss (R-IB line) remain sensitive to exogenous IPG suggests that resistance to the antiproliferative effects of TGF-ss is linked to the absence of generation of IPG after treatment with TGF-ss.

The alteration of this signaling mechanism could be at the origin of certain tumors (Bogdanowicz et al. (1996) Cell. Signal. 8,503-509; Bogdanowicz et al.

(2000) Moll. Cell. Biochem. 208.143-150).

protéines (GPI de T. brucei) ou plus récemment avec un IPG de synthèse (Frick et al. (1998) Biochemistry 37,13421-13436). Ces molécules peuvent induire la phosphorylation de la protéine IRS-l, l'activation de la PI-3kinase et la translocation de GLUT-4 sans affecter l'état de phosphorylation de la sous-unité ss du récepteur de l'insuline. Ces résultats confirment que ces molécules doivent nécessairement contenir un certain nombre de résidus osidiques pour mimer les effets de l'insuline. Toutefois, il est difficile de prévoir l'activité des molécules, à moins d'identifier une structure de base qui confère l'activité, ou l'essentiel de l'activité, biologique recherchée, démontrée par des tests biologiques, et sur laquelle différents radicaux peuvent être greffés sans altérer de manière non souhaitée cette activité. Les inventeurs ont réussi à identifier une telle structure de base disaccharidique décrite plus loin. The first works attempting to establish structure-activity relationships were carried out with IPG type molecules purified from GPI anchoring

proteins (GPI of T. brucei) or more recently with a synthetic IPG (Frick et al. (1998) Biochemistry 37,13421-13436). These molecules can induce the phosphorylation of the protein IRS-1, the activation of PI-3kinase and the translocation of GLUT-4 without affecting the state of phosphorylation of the ss subunit of the insulin receptor. These results confirm that these molecules must necessarily contain a certain number of sugar residues to mimic the effects of insulin. However, it is difficult to predict the activity of molecules, unless you identify a basic structure which confers the activity, or most of the activity, biological desired, demonstrated by biological tests, and on which different radicals can be grafted without undesirably altering this activity. The inventors have succeeded in identifying such a basic disaccharide structure described below.

<Desc / Clms Page number 5>

 Furthermore, the biochemical methods currently available make it very difficult to isolate, from microorganisms, IPG having a purity index sufficient to envisage therapeutic applications. To date, only chemical synthesis can make it possible to obtain pure IPG molecules in sufficient quantity (WO 99/38516, WO 99/37309, WO 00/64454, WO 96/29063, US 00/6004938).

 In view of the prior art recalled, there is always the need to obtain new therapeutically effective IPG type compounds, the synthesis of which is simple enough for industrial production, and making it possible to act on the same targets as IPG endogenous. The invention also aims to obtain chemically pure compounds, not isolated from mammals, in order to avoid numerous risks of toxicity, for example BSE. Another object of the invention is to obtain compounds which do not have their own toxicity or immunogenicity.

dans laquelle : - RI est choisi dans le groupe constitué par OH, un oligosaccharide, un polysaccharide, et R2=R3=OH, ou au moins un des groupes RI, R2, R3 est un groupe capable de modifier la lipophilie du composé A, l'autre ou les deux autres de ces trois groupes étant
OH ; et - R4 est choisi dans le groupe constitué par OH, NH2, un groupe capable de modifier la lipophilie du composé A, et - R6 est H ou CH2OH, et To this end, the subject of the invention is, according to a first aspect, a compound of formula

in which: - RI is chosen from the group consisting of OH, an oligosaccharide, a polysaccharide, and R2 = R3 = OH, or at least one of the groups RI, R2, R3 is a group capable of modifying the lipophilicity of compound A, the other or the other two of these three groups being
OH ; and - R4 is chosen from the group consisting of OH, NH2, a group capable of modifying the lipophilicity of compound A, and - R6 is H or CH2OH, and

<Desc / Clms Page number 6>

 - X is chosen from 0, NH, S, CH2, and - R5 is chosen from OH, an oligosaccharide, a polysaccharide, a group capable of modifying the bioavailability of compound A, and its pharmaceutically acceptable salts The invention relates in a very advantageous compound A as a medicament. The inventors have in fact, surprisingly, succeeded in obtaining particularly active compounds compared to the prior art, by using a heterocycle instead of an inositol cycle, unlike the known compounds.

The invention also relates to the isomers of compound A.

According to a preferred embodiment, R1 = R2 = R3 = OH, and R4 is OH or NH2.

According to one embodiment, R5 = OH, R6 = H.

Selon une réalisation X est une liaison ss, le composé A étant

Selon une réalisation préférée, l'invention concerne un composé de formule 1 suivante :

According to one embodiment X is a bond a, the compound A being

According to one embodiment X is an ss bond, the compound A being

According to a preferred embodiment, the invention relates to a compound of formula 1 below:

<Desc / Clms Page number 7>

 , in which: - X is chosen from 0, S, N - R7 is OH or a hexose - R8 is chosen from OH, NH2, as a medicament.

, dans laquelle : - X est choisi parmi 0, S, N
R7 est OH ou un hexose - R8 est choisi parmi OH, NH2 , en tant que médicament. According to a preferred embodiment, the invention relates to a compound of formula II below:

, in which: - X is chosen from 0, S, N
R7 is OH or a hexose - R8 is selected from OH, NH2, as a drug.

The invention relates, according to preferred embodiments, to the compounds of formula 1 or II, in which the non-cyclic phosphate ring is chosen from glucose, mannose, galactose, glucosamine, mannosamine, galactosamine.

The invention relates, according to preferred embodiments, to the compounds of formula 1 or II, in which the ring carrying the cyclic phosphate is chosen from a pentose (for example lyxose, ribose) in configuration D or L, a hexose (for example glucose, mannose , galactose.).

According to particularly advantageous embodiments, the invention relates to the compounds FC663, FC669, FC670, FC671.

According to one embodiment, the invention relates to a compound of formula A, and having a biological activity of at least 10% of that of compound I, preferably at least 30.50, 80.100% of this activity.

According to one embodiment, the invention relates to a compound of formula A, and having a biological activity of at least 10% of that of compound B, preferably at least 30.50, 80.100% of this activity.

<Desc / Clms Page number 8>

 The invention thus also relates to the compounds derived from formula A, the biological activity of which is validated by appropriate in vitro and / or in vivo biological activity tests. Among the appropriate tests, use will be made, according to one embodiment, of the activity test described in detail later in the description produced, developed for the compounds FC663, FC669, FC670, FC671, or related tests which are now carried out without undue difficulty by the skilled in the art on these derivative compounds in view of this document.

The groups capable of modifying lipophilicity are known to those skilled in the art, in particular by determining the Log P value, according to appropriate methods.

The nature and size of the radicals RI, R2, R3, R4, RS, R6 will influence the lipophilicity of compound I and / or its bioavailability. Various lipophilic groups, intended to facilitate contact with the cell membrane, are known to those skilled in the art. Overall, if these groups are large, bioavailability will be reduced due to steric hindrance while lipophilicity will be increased. The choice of radicals RI to R6, and in particular of RI and R5, will typically be made according to the difficulty of synthesis of the IPG and the therapeutic efficacy obtained. If necessary, different compounds will be prepared by their synthesis scheme and their therapeutic efficacy as a function of the main objective sought.

Among lipophilic groups, particular preference will be given, according to one embodiment, to saturated or unsaturated linear or branched aliphatic chains. According to a preferred embodiment, the group or groups capable of modifying lipophilicity are chosen from: a) an alkyl group, linear or branched, comprising less than 20 carbon atoms; b) a cycloalkyl group comprising less than 10 carbon atoms; c) an alkenyl group, linear or branched, comprising less than 20 carbon atoms; d) a cyclo-alkenyl group comprising less than 10 carbon atoms; e) an aryl group comprising less than 20 carbon atoms; f) an aralkyl group comprising less than 20 carbon atoms;

<Desc / Clms Page number 9>

 g) a heteroaryl group comprising 4 to 9 carbon atoms and at least one heteroatom chosen from oxygen, nitrogen, sulfur; h) a heterocyclic group, comprising 2 to 9 carbon atoms and at least one heteroatom chosen from oxygen, sulfur and nitrogen.

 However, this embodiment is not limiting, the lipophilic group or groups may be more generally: - a linear or branched alkylene, alkenyl or alkenene group, these groups may be substituted by an oxa, aza, thia or a combination of at least two groups linked by a single or double bond or a bond 0, S, SO, CON; - an alkyl, alkenyl, mono-or bi-cycloalkyl, aryl, heteroaryl, mono- or bicycloalkylalkyl, mono- or bicycloalkylalkenyl, arylalkyl, aralkyl, heteroarylalkyl, arylalkenyl, heteroarylalkenyl, alkarylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkylalkyl, arylalkyl, arylalkyl, aralkyl, heteroarylalkyl, azarycloalkylalkylalkylalkylalkylalkylalkyl , mono or bicyclo heteroaromatic; - a group chosen from CH3 (CH2) n CH (COOH) NH - CO (CH2) 2 CO-, CH3 (CH2) r CO - NHCH (COOH) (CH2) 2 CO -, - NHCH (COOH) ( CH2) 4 NH - CO (CH2) m CHs, - NHCH (COOH) (CH2) 4 NH - COCH ((CH) 2 COOH) NH-CO (CH2) p CH3, n, m, r, p being an integer between 5 and 15; - an aryl lipophilic group (including bicyclic aryl groups) unsubstituted or substituted with one, two or three substituents independently chosen from lower alkyl, haloalkyl, alkoxy, thioalkoxy, amine, alkylamino, dialkylamino, hydroxy, halo, mercapto, sulfhydryl radicals , nitro, cyano, carboxaldehyde, carboxy, alkoxycarbonyl, haloalkyl-C (O) -NH-, haloalecenylC (O) -NH and carboxamide (in addition, substituted aryl groups include tetrafluorophenyl and pentafluorophenyl); - a steroid derivative, a natural or synthetic lipid, a saccharide capped by an aliphatic or cycloaliphatic unit.

The term "alkenyl" refers to a straight or branched chain hydrocarbon containing from 2 to 10 carbon atoms and also containing at least one C = C double bond. Examples of alkenyl include -CH = CH2, -CH2CH = CH2, - C (CH3) = CH2, -CH2CH = CHCH3, and the like.

<Desc / Clms Page number 10>

 The term "aryl" refers to a carbocyclic system comprising at least one aromatic ring, and refers in particular to the phenyl, piridyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl and the like radicals.

The term "arylalkyl" refers to a lower alkyl radical to which an aryl group is added. Mention will in particular be made of benzyl and phenylethyl groups, hydroxybenzyl, fluorobenzyl and fluorophenylethyl.

The term "cycloalkyl", mono or poly cycloalkyl, preferably refers to an alicyclic group comprising from 3 to 10 carbon atoms, in particular the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbomyl, adamantyl groups. The cycloalkyl groups can be optionally substituted.

 The term "lower alkyl" refers to branched or straight chain alkyl groups, optionally substituted, having one to ten carbon atoms, especially methyl, ethyl, propyl, isopropyl, butyl, isopentyl groups.

The term "oxo" means (= 0). The term Bn means jQ. The invention relates, according to another aspect, to a compound A in configuration ss, and preferably, a compound compound of formula (H) capable of mimicking the action of insulin for the treatment of diseases due deficient glucose metabolism. The inventors have indeed demonstrated that such compounds (II) are capable of mimicking the action of insulin on the uptake of glucose in adipocytes as well as on the synthesis of glycogen in hepatocytes. These molecules can be used in the treatment of disorders of glucose metabolism such as glucose intolerance, hyperglycemia associated with non-insulin dependent diabetes, insulin resistance and their chronic complication. Insulin resistance can result from disorders such as obesity, hyperlipidemia, dyslipidemia, atherosclerosis, hypertension, cardiovascular pathologies, AIDS, cancers, cachexia, septicemia, trauma associated with burns, malnutrition, stress, age, lupus and other autoimmune pathologies, endocrine disorders, hyperuricemia, polycystic ovarian syndrome and complications due to sports activity or inactivity.

The invention also relates to the use of a compound A in the ss configuration, and preferably of a compound II, for the preparation of a medicament against disorders due to a deficient glucose metabolism.

<Desc / Clms Page number 11>

 The invention also relates to a method of treating disorders due to a deficient glucose metabolism comprising the use of a compound A in the ss configuration, and preferably a compound II.

According to another aspect, the invention also relates to the use of a compound A in configuration a, and preferably a compound of formula I, for the treatment of diseases associated with excessive cell proliferation, in particular cancer, psoriasis, the rheumatoid pannus.

 The inventors have in fact demonstrated that compounds of formula (I), of the inositolphosphate glycan (IPG) type, are capable of strongly inhibiting the proliferation of cells, and in particular of cells originating from a human adenocarcinoma line SW- 480, as will be described later. These molecules can be used in the treatment of pathologies with excessive cell proliferation such as cancer, psoriasis, rheumatoid pannus synovial.

According to another aspect the invention relates to a pharmaceutical composition comprising a pharmaceutically effective amount of a compound A as described above, preferably a compound 1 or a compound II, and a phannaceutically acceptable vehicle.

The invention also relates to the use of a compound A in configuration a, and preferably of a compound of formula I, for the preparation of a medicament against diseases associated with excessive cell proliferation, in particular cancer, psoriasis, rheumatoid pannus.

The invention also relates to a method of treating diseases associated with excessive cell proliferation, in particular cancer, psoriasis, rheumatoid pannus, comprising the use of a compound I.

According to another aspect, the invention relates to a process for obtaining formula I or H, in which X = O and R4 = OH, comprising the steps:

<Desc / Clms Page number 12>

- étape 2 : désacétalisation des intermédiaires obtenus à l'étape 1, - étape 3 : cyclisation et déprotection des intermédiaires obtenus à l'étape 2. - step 1: mixing of the compounds (1) and (2) of formulas

- step 2: deacetalization of the intermediates obtained in step 1, - step 3: cyclization and deprotection of the intermediates obtained in step 2.

- étape 2 : désacétalisation des intermédiaires obtenus à l'étape 1, - étape 3 : déprotection des intermédiaires obtenus à l'étape 2. The invention relates according to another aspect to a process for obtaining formula 1 or n, in which X = O and R4 = NH2, comprising the steps: - step 1: mixing of the compounds (9) and (2) of formulas

- step 2: deacetalization of the intermediates obtained in step 1, - step 3: deprotection of the intermediates obtained in step 2.

According to one embodiment, the pharmaceutically effective amount of compound A, and preferably of compound 1 or n administered, corresponds to a dose typically of the order of 10 μg / kg / day to 100 mg / kg / day of body weight. Preferably the dose will be of the order of 0.1 to 1 mg / kg / day. For continuous parenteral administration, the dosage may for example be of the order of 50 μg / kg / hour to 1 mg / kg / hour, in several injections / day or by continuous subcutaneous infusion.

The pharmaceutical compositions comprising the inositolphosphate glycan type molecules of formula A described above can be formulated in different ways. In addition to one or more synthetic IPGs of formula A, preferably of formula 1 or n, these pharmacologically acceptable formulations can also comprise an excipient, a transporter, a buffer, a stabilizer or any other suitable substance. The term carrier or vehicle

<Desc / Clms Page number 13>

pharmacologiquement acceptable"signifie un solide non toxique, un contenant semi-solide ou liquide, une substance d'encapsulation ou une substance auxiliaire de quelque type que ce soit. De telles substances ne doivent pas interférer avec l'efficacité du ou des principe (s) actif (s). La nature précise du transporteur ou du matériel dépend de la voie d'administration, par exemple orale, rectale, intravaginale, topique (comme des poudres, onguents, gouttes ou patch transdermiques), intraveineuse, cutanée ou subcutanée, nasale, intramusculaire, intrasternale, intrapéritonéale, par injection ou perfusion intraarticulaire. On peut par exemple utiliser comme transporteur de l'eau, une solution saline, une solution de Ringer, une solution de dextrose, une solution non aqueuse contenant des huiles ou des liposomes, de la vaseline, des huiles végétales, animales, minérales ou synthétiques.

pharmacologically acceptable "means a non-toxic solid, a semi-solid or liquid container, an encapsulating substance or an auxiliary substance of any kind. Such substances must not interfere with the efficacy of the principle (s) active) The precise nature of the carrier or material depends on the route of administration, for example oral, rectal, intravaginal, topical (such as powders, ointments, transdermal drops or patch), intravenous, cutaneous or subcutaneous, nasal, intramuscular, intrasternal, intraperitoneal, by intraarticular injection or infusion, for example water, saline, Ringer's solution, dextrose solution, non-aqueous solution containing oils or liposomes can be used as a carrier , petroleum jelly, vegetable, animal, mineral or synthetic oils.

The suitable transporters may contain additives which in particular increase the chemical stability of the composition, for example: buffers (such as phosphates, citrates, succinates, organic acids), antioxidants, low molecular weight peptides, proteins (gelatin, serum albumin), hydrophilic polymers (polyvinyl pyrrolidones), amino acids, saccharides (glucose, dextrin), chelating agents (EDTA), nonionic surfactants (ethylene glycol, propylene glycol, polyethylene glycol). A compound according to the invention is typically formulated at a concentration of approximately 0.1 mg / ml to 100 mg / ml, in particular from 0.1 to 10 mg / ml. The invention also relates to the use of salts of the compounds according to the invention, the use of certain transporters or other excipients being able to involve the formation of such salts according to the substituents of the disaccharides according to the invention.

The compounds of the present invention are typically stored as unit doses in suitable containers, or as an aqueous solution or lyophilized formulation.

The formulations for oral administration can be presented in particular in the form of tablets, capsules, powder or liquid. A tablet may include an excipient / carrier such as gelatin or an adjuvant.

 For intravenous, cutaneous or subcutaneous injections, synthetic IPGs of formula A, and preferably of formula 1 or H, are in the form of an acceptable aqueous solution in parenteral form, that is to say in the absence of

<Desc / Clms Page number 14>

 pyrogen, at adequate pH, isotonicity and stability (eg NaCI, Ringer's solution, or Ringer-lactate solution).

 Prescription of the compounds of this present invention is preferably done, for each individual, at prophylactic or therapeutic dosages sufficient to exert a beneficial action (antiproliferative effects, appropriate treatment of glucose metabolism disorders such as glucose intolerance, hyperglycemia associated with DNID and any form of insulin resistance).

The dosage and method of administration will depend on the nature and severity of the condition to be treated.

susmentionnés peuvent être retrouvés dans :"Remington's Pharmaceutical Sciences, 1 6th edition, Oslo, A. (ed), 1980". Treatment decisions, such as dosage, are the responsibility of the treating physicians. They must take into account the pathologies to be treated, the patient, the mode of administration in particular. These different examples

mentioned above can be found in: "Remington's Pharmaceutical Sciences, 1 6th edition, Oslo, A. (ed), 1980".

Thanks to the work carried out by the inventors, the compounds obtained present an easier synthesis than that of the known compounds, these compounds being moreover not recognized by enzymes usually in charge of the metabolism of sugars. In addition, the IPG molecules obtained do not exhibit acute (short term) nor chronic (long term) toxicities.

Other objects and advantages of the description will become apparent with the aid of the detailed description which follows, illustrated by the figures: - Figure l. a: effect of compound FC663 on proliferation of SW-480 cells - Figure 1. b: effect of compound FC669 on proliferation of SW-480 cells - Figure 2. a: effect of compound FC670 on glycogen synthesis at level d HepG2 hepatocytes.

 - Figure 2.b: effect of compound FC671 on glycogen synthesis in HepG2 hepatocytes.

 - Figure 3. a: effect of compound FC670 on the uptake of glucose at the level of 3T3-L1 adipocytes.

 - Figure 3.b: effect of compound FC671 on the uptake of glucose at the level of 3T3-L1 adipocytes.

<Desc / CRUD Page number 15>

 The synthetic diagrams and the test results described in detail are presented by way of illustration and not limitation, using four example compounds, corresponding to formulas I or II, having particularly advantageous properties, and designated FC663, FC669 , FC670, FC671.

The synthesis of compounds FC663 and FC671 was carried out according to the following reaction schemes.

<Desc / Clms Page number 16>

The synthesis and structure of the molecules are detailed below.

Synthesis of compounds 3 and 4.

0.580 g (2.07 mmol) of compound 2 (GE Keck, TT Wager, J. Org. Chem. 61 (1996) 8366-8367) and 2.12 g (3.1 mmol) of compound 1 are added dissolved in 20 ml of anhydrous methylene chloride and then 1 g of molecular sieve (4 A) are added. The suspension is stirred at -30 ° C. for 15 minutes and then 1 ml of a 0.2 molar solution of trimethylsilyltrifluoromethane sulfonic acid in methylene chloride is added. The reaction mixture is stirred at -30 C for 1 hour then it is allowed to return to room temperature. The suspension is filtered through celite and the filtrate is concentrated under reduced pressure. Compounds 3 (0.750 g, 45%) and 4 (0.450 g, 27%) are obtained pure by chromatography on silica gel. Compound 3 is a colorless oil. Rf = 0.39 (hexane / ethyl acetate 8: 2); [a] D = +52 (c = 3.1 CHCl3); 1H NMR (CDCl3) # 5.32 J = 4 Hz, signal characteristic of an anomeric proton of configuration a of a glucose residue; analysis calculated for CHOlo:% C = 73.3,% H = 6.8; found:% C = 73.59,% H = 6.61.

proton anomère de configuration P d'un résidu glucose ; analyse calculée pour C49H54Ûl0 : % C = 73, 3, % H = 6, 8 ; trouvée : % C = 73, 42, % H =6, 75 Synthèse du composé 5. Compound 4 is a colorless oil. Rf = 0.35 (hexane / ethyl acetate 8: 2); [a] D = +24 (c = 1.4 CHCl3); 1H NMR (CDCIs) 8 4.55 J = 8 Hz, signal characteristic of a

anomeric proton of configuration P of a glucose residue; analysis calculated for C49H54Ûl0:% C = 73, 3,% H = 6, 8; found:% C = 73, 42,% H = 6, 75 Synthesis of compound 5.

purification sur colonne de gel de silice. Rf = 0, 51 (hexane/acétate d'éthyle 5 : 5) ; IOEID = +60 (c = 0, 9 CHCIs) ; analyse calculée pour C46H50ÛlO : %C = 72, 4, % H = 6, 6 ; trouvée : % C = 72, 71, % H =6, 69. 0.750 g (0.93 mmol) of compound 3 are dissolved in 3 ml of tetrahydrofuran (THF) and then 20 ml of an aqueous solution of acetic acid at 70% are added to this solution. The reaction mixture is heated at 60 ° C. for 5 hours. The solvents are evaporated under reduced pressure and the residue is coevaporated 2 times with toluene. Compound 5 (0.524 g, 74%) is obtained pure in the form of a colorless oil by

purification on a silica gel column. Rf = 0.51 (hexane / ethyl acetate 5: 5); IOEID = +60 (c = 0.9 CHCIs); analysis calculated for C46H50ÛlO:% C = 72, 4,% H = 6, 6; found:% C = 72, 71,% H = 6, 69.

<Desc / Clms Page number 17>

Synthesis of compound 7.

préparation du composé 5. Rf= 0, 46 (hexane/acétate d'éthyle 5 : 5) ; F = 139 C, [a] D = +41 (c = 0,7 CHC13) ; analyse calculée pour C46H5001O : % C = 72, 4, % H = 6,6 ; trouvée : % C = 72,35, % H =6,45. Compound 7 (0.314 g, 70%) is obtained in the form of a white powder by treatment of 0.450 g (0.59 mmol) of compound 4 according to the protocol described for

preparation of compound 5. Rf = 0.46 (hexane / ethyl acetate 5: 5); F = 139 C, [a] D = +41 (c = 0.7 CHC13); analysis calculated for C46H5001O:% C = 72, 4,% H = 6.6; found:% C = 72.35,% H = 6.45.

Synthesis of compounds FC663 and FC671.

3 g of triazole are dissolved in 80 ml of THF, the resulting solution is cooled to 10 ° C., then 1.35 ml of phosphorus oxychloride and then 6 ml of triethylamine are added dropwise successively. The reaction mixture is then stirred at room temperature for 15 minutes. The precipitate formed during the reaction is filtered and then washed with a little anhydrous THF.

0.2 g (0.26 mmol) of compound 5 or 7 are dissolved in 2 ml of anhydrous THF and then 30 ml of the previously obtained filtrate are added. The reaction volume is reduced to 5 ml by concentration under reduced pressure. The reaction mixture is stirred at room temperature for 15 minutes and then diluted with 70 ml of ethyl acetate.

The organic phase is washed twice with 2 ml of water, decanted, dried magnesium sulphate, then concentrated. The residue contains cyclic phosphate (31 p NMR ô 14.2 ppm) which is used without purification for the deprotection step. The cyclic phosphate is dissolved in 20 ml of a THF / EtOH / HO mixture (1: 1: 1) and then stirred for 20 hours under a hydrogen atmosphere in the presence of 20 mg of triethylammonium hydrogen carbonate and 160 mg of palladium. on 10% charcoal. The catalyst is filtered through celite and rinsed with water. The filtrate is concentrated under reduced pressure. The residue is diluted with 1 ml of water and purified using a C18 isolute SPE column to provide, after lyophilization, the compound FC663 or FC671 in the form of triethylammonium salt.

The synthesis of compounds FC669 and FC670 was carried out according to the following reaction schemes.

<Desc / Clms Page number 18>

Synthesis of compounds 10 and 11.

0.500 g (1.78 mmol) of compound 2 (GE Keck, TT Wager, J. Org. Chem. 61 (1996) 8366-8367) and 1.65 g (2.67 mmol) of compound 9 (W. Kinzy , RR Schmidt, Liebigs

<Desc / Clms Page number 19>

Ann. Chem. (1985), 1537-1545) sont mis en solution dans 20 ml de chlorure de méthylène anhydre puis 19 de tamis moléculaire (4 Â) sont ajoutés. La suspension est agitée à-30 C pendant 15 minutes puis on ajoute 1 ml d'une solution 0, 2 molaire d'acide triméthylsilyltrifluorométhane sulfonique dans du chlorure de méthylène. Le mélange réactionnel est agité à-30 C pendant 1 heure puis il est laissé revenir à température ambiante. La suspension est filtrée sur de la célite et le filtrat est concentré sous pression réduite. Les composés 10 (0,537 g, 41%) et 11 (0,557 g, 44%) sont obtenus purs par chromatographie sur gel de silice. Le composé 10 est une poudre blanche. Rf= 0,41 (hexane/acétate d'éthyle 8 : 2) ; F = 85OC ; [a] D = +73 (c = 0,54 CHC13) ; 1H RMN (CDC13) 8 5,34 J = 4 Hz, signal caractéristique d'un proton anomère de configuration a d'un résidu glucose ; analyse calculée pour

C42H47N309 : % C = 68, 4, % H = 6, 4, % N = 5, 7 ; trouvée : % C = 68, 71, % H = 6, 64, % N = 5,46.

Ann. Chem. (1985), 1537-1545) are dissolved in 20 ml of anhydrous methylene chloride and then 19 of molecular sieve (4 Å) are added. The suspension is stirred at -30 ° C. for 15 minutes and then 1 ml of a 0.2 molar solution of trimethylsilyltrifluoromethane sulfonic acid in methylene chloride is added. The reaction mixture is stirred at -30 ° C. for 1 hour then it is allowed to return to ambient temperature. The suspension is filtered through celite and the filtrate is concentrated under reduced pressure. Compounds 10 (0.537 g, 41%) and 11 (0.557 g, 44%) are obtained pure by chromatography on silica gel. Compound 10 is a white powder. Rf = 0.41 (hexane / ethyl acetate 8: 2); F = 85OC; [a] D = +73 (c = 0.54 CHCl3); 1 H NMR (CDCl3) 8 5.34 J = 4 Hz, signal characteristic of an anomeric proton of configuration a of a glucose residue; analysis calculated for

C42H47N309:% C = 68, 4,% H = 6, 4,% N = 5, 7; found:% C = 68, 71,% H = 6.64,% N = 5.46.

Compound 11 is a white powder. Rf = 0.38 (hexane / ethyl acetate 8: 2); F = 89 C [a] D = +15.3 (c = 1.2 CHC13); 1H NMR (CDCl3) ô 4.42 J = 7.5 Hz, signal characteristic of an anomeric proton of configuration p of a glucose residue; analysis calculated for C42H47N309:% C = 68.4,% H = 6.4,% N = 5.7; found:% C = 68.52,% H = 6.35,% N = 5.82.

Synthesis of compound 12.

0.287 g (0.39 mmol) of compound 10 is dissolved in 3 ml of tetrahydrofuran (THF) and then 20 ml of an aqueous solution of acetic acid at 70% are added to this solution. The reaction mixture is heated at 60 ° C. for 5 hours. The solvents are evaporated under reduced pressure and the residue is coevaporated 2 times with toluene. Compound 12 (0.293 g, 75%) is obtained pure in the form of a gum by purification on a column of silica gel. Rf = 0.56 (hexane / ethyl acetate 5: 5); [a] D = +60.5 (c = 1.3 CHCl3); analysis calculated for C39H49N309:% C = 67.1,% H = 6.2,% N = 6.0; found:% C = 66.95,% H = 5.89,% N = 5.78.

<Desc / Clms Page number 20>

Synthesis of compound 14.

Compound 14 (0.334 g, 84%) is obtained in the form of a white foam by treatment of 0.400 g (0.54 mmol) of compound 11 according to the protocol described for the preparation of compound 12. Rif = 0.39 (hexane / ethyl acetate 5: 5); [aJD = +41.4 (c = 1.2 CHCIs); analysis calculated for C39H49N309:% C = 67.1,% H = 6.2,% N = 6.0; found:% C = 66.99,% H = 6.02,% N = 5.88.

Synthesis of compounds FC669 and FC670.

3 g of triazole are dissolved in 80 ml of THF, the resulting solution is cooled to 10 ° C., then 1.35 ml of phosphorus oxychloride and then 6 ml of triethylamine are added dropwise successively. The reaction mixture is then stirred at room temperature for 15 minutes. The precipitate formed during the reaction is filtered and then washed with a little anhydrous THF.

0.209 g (0.3 mmol) of compound 12 or 14 are dissolved in 2 ml of anhydrous THF and then 30 ml of the previously obtained filtrate are added. The reaction volume is reduced to 5 ml by concentration under reduced pressure. The reaction mixture is stirred at room temperature for 15 minutes and then diluted with 70 ml of ethyl acetate. The organic phase is washed twice with 2 ml of water, decanted, dried magnesium sulphate, then concentrated. The residue contains cyclic phosphate (31p NMR 14.2 ppm) which is used without purification for the deprotection step. The cyclic phosphate is dissolved in 20 ml of a THF / EtOH / H2O mixture (1: 1: 1) and then stirred for 20 hours under a hydrogen atmosphere in the presence of 20 mg of triethylammonium hydrogen carbonate and 160 mg of palladium. on 10% charcoal. The catalyst is filtered through celite and rinsed with water. The filtrate is concentrated under reduced pressure. The residue is diluted with 1 ml of water and purified using a C18 isolute SPE column to provide, after lyophilization, the compound FC669 or FC670 in the form of triethylammonium salt.

The activity of the compounds was evaluated according to the following methods.

 The molecules synthesized are tested on various parameters, to determine their anti-proliferative and insulin-mimetic properties. Measures

<Desc / Clms Page number 21>

 performed to assess insulin-mimetic activity systematically include a positive control (insulin).

The experiments described below evaluate the biological activities of the four previously described molecules, designated: FC663, FC669, FC670 and FC671.

l'isobutylméthylxanthine (IBMX) proviennent de chez SIGMA. Equipment
RPMI 1640, DMEM, fetal calf serum "SVF" and donor calf serum "SVD" are supplied by Life Technologies. D [2-3H] glucose (21.00 Ci / mmol) and [6} H] 2-deoxyglucose (6.10 Ci / mmol) are obtained from NEN Life Science. The Celltiter 96 reagent comes from Promega. All chemicals as well as insulin, glycogen, dexamethasone and

isobutylmethylxanthine (IBMX) comes from SIGMA.

3T3-L1 cell lipids: line of pre-adipocytes selected from the mouse fibroblast line 3T3 for their ability to differentiate into adipocytes under certain experimental conditions.

 HepG2: human hepatocarcinoma line (ATCC n: HB-8065).

 SW-480: human colorectal adenocarcinoma line (ATCC number: CCL-228).

The cells are kept in culture in DMEM + SVF 10% (SW480), in RPMI + SVF 10% + insulin 0.5% + BSA 5% (HepG2) and in DMEM + SVD 10% (3T3-L1) , in an atmosphere containing 5% C02 and 95% air. These media are supplemented with penicillin (100U / ml), streptomycin (100 G / ml) and fungizone (0.25 μg! Ml).

Differentiation of 3T3-LI cells The cells (3T3-LI) are cultured in 6-well plates (3.105 cells / well) in the presence of DMEM + 10% SVD. At confluence, the medium is replaced by DMEM + 10% FCS containing dexamethasone (25 M), isobutylmethylxanthine (100 M) and insulin (170nM) in order to induce the differentiation of fibroblasts (3T3-L1) into fat cells. Two days later, the cells are incubated for 4 to 6 days in the DMEM differentiation medium + 10% FCS + insulin

<Desc / Clms Page number 22>

 170 nM. The cells are used for the measurement of glucose uptake when approximately 80 to 90% contain lipid vacuoles (phenotypic marker).

1 mol de NaOH 0, 1N renfermant du SDS 0, 1%. Enfin, la mesure est effectuée dans un compteur à scintillation liquide. Measurement of glucose uptake
When the cells are differentiated, 2 washes are carried out with DMEM followed by another washing with KRH buffer + 1% BSA + 5mM Glc. Then, the cells are incubated in the presence of the various molecules at the indicated concentrations (100.50 and 25 μM) for 20 minutes. Then, 10 μl of the mixture [6 ~ 3H] 2-deoxyglucose + glucose with ImM are added to each well. Twenty minutes later, 3 washes are carried out with 5 mM KRH + Glc (4 C), followed by lysis of the cells by

1 mol of 0.1N NaOH containing 0.1% SDS. Finally, the measurement is carried out in a liquid scintillation counter.

Colorimetric measurement of cell proliferation
The principle of this method is based on the capacity of living cells to convert the tetrazolium salts, contained in Celltiter96 (8), into formazan. The cells (SW480) are seeded in 96-well plates (5.13 cells / well) in DMEM + 10% FCS. After 48 hours, the cells are incubated in the presence of the different concentrations of the molecules for 24 hours. After 20 h, 20 μl of reagent are added to each well and the absorbance is measured at 490 nm, after 4 hours, with a plate reader (SpectraCount; Packard).

puis incubés avec les différentes molécules. Après 30 minutes, le 6eH]-D glucose est additionné (2/lCi/ml). Après 4 h de marquage métabolique, les tapis cellulaires sont rincés avec du PBS 4 C, puis lysés par de la soude 0. 1M. Une fraction aliquote de 5 Oui est prélevée pour mesurer la concentration protéique par la méthode de Bradford. Le glycogène est précipité, 2h à-80 C, par 5 volumes d'éthanol en présence d'un entraîneur (5 mg de glycogène). Après centrifugation (15 min. à 6000g) le culot est repris par 500ul d'H20 puis la radioactivité est mesurée. Svnthèse de jvcojène
The hepatocytes are seeded in 6-well plates (2.106 cells / well) in the presence of RPMI + SVF 10% + insulin 0.5% + BSA 5%. After 2 days, the cell mats are incubated for 3 h in RPMI + 5mM glucose,

then incubated with the different molecules. After 30 minutes, the 6eH] -D glucose is added (2 / lCi / ml). After 4 h of metabolic labeling, the cell mats are rinsed with PBS 4 C, then lysed with 0.1 M sodium hydroxide. An aliquot of 5 Yes is taken to measure the protein concentration by the Bradford method. The glycogen is precipitated, 2 h at -80 ° C., with 5 volumes of ethanol in the presence of a entrainer (5 mg of glycogen). After centrifugation (15 min. At 6000 g) the pellet is taken up in 500 μl of H 2 O then the radioactivity is measured.

<Desc / Clms Page number 23>

Statistical analyzes
The results are the average of 4 wells (glycogen synthesis and glucose uptake tests) or 8 wells (proliferation). The significance of the results is determined using the Student test (*: p <0.05; **: p <0.01; ***: p <0.005).

The results obtained are as follows.

mesuré une inhibition d'environ 34 % dès 25 uM pour atteindre 65 % à 100 uM (Fig. la). Le composé FC669 exerce également un effet inhibiteur très marqué qui est mesurable à partir de 25 jiM (-35 %). L'effet inhibiteur dépend de la concentration utilisée puisqu'il atteint 70 % à 100 ! M (Fig. lob). Dans les figures la et 1b, les cellules sont ensemencées dans des plaques de 96 puits et incubés en présence ou en absence des composés à tester FC663 et FC669 à différentes concentrations pendant 24heures. Le réactif colorimétrique est rajouté pendant les 4 dernières heures. La prolifération cellulaire est mesurée par lecture densitométrique à 490nm (** : p < 0, 01 ; *** : p < 0,005). 1) Antivroliferative effects of tvve molecules (1)
After 24 hours of incubation, the compound FC663 exerts, on proliferation, an inhibitory effect directly proportional to the concentrations. So, we have

measured an inhibition of approximately 34% from 25 uM to reach 65% at 100 uM (Fig. la). The compound FC669 also exerts a very marked inhibitory effect which is measurable from 25 µm (-35%). The inhibitory effect depends on the concentration used since it reaches 70% to 100! M (Fig. Lob). In FIGS. 1 a and 1 b, the cells are seeded in 96-well plates and incubated in the presence or absence of the test compounds FC663 and FC669 at different concentrations for 24 hours. The colorimetric reagent is added during the last 4 hours. Cell proliferation is measured by densitometric reading at 490nm (**: p <0.01; ***: p <0.005).

2) Insulin-mimetic effects of tvpe (II) molecules
A / Effetssurlasynthèsedeglycogènechezleshépatocytes
The hepatocytes of the HepG2 line were incubated, for 4 hours, in the presence of different concentrations (100.50, 25 and 10 μM) of the test compounds, or in the presence of insulin (5 and 1 μM) used as positive control . We measured an increase in neo-synthesis of glycogen in the presence of insulin. From one experiment to another, this stimulation amounts to approximately 30 to 35% for the concentration of 5 p. M to reach 40 to 50% at 1 M. (Fig. 2 a, b). The FC670 compound clearly stimulates the synthesis of glycogen from 50% to 100! M and from 35% to 50 M. No significant effect was measured at the lower concentrations (Fig. 2a). The compound FC671 also exerts a stimulating effect on the synthesis of glycogen. This effect can be measured from the concentration of 25 uM with a

<Desc / Clms Page number 24>

 30% increase. This stimulation reaches 65% at 50 uM and 52% at 100 uM (Fig. 2b). In FIGS. 2a and 2b, the cells are seeded in 9.6 cm 2 plates and then incubated for 4 hours with the compounds FC670 and FC671 or with insulin (positive control) in the presence of DeH-2] glucose as described in the materials and methods chapter. The synthesis of glycogen is measured by the incorporation of tritiated glucose and related to the amount of total protein.

(*: p <0.05; ***: p <0.005).

B Effects on glucose uptake in adipocytes:
The 3T3-L1 differentiated into adipocytes were incubated for 40 minutes in the presence of insulin (positive control) or of the compounds FC670 and FC671 (100, 50 and 25 aM). In both experiments, insulin stimulated uptake of [6-3H] 2-deoxyglucose by adipocytes by around 40% compared to the control (Fig. 3a, b). FC670 (50 or 100 Ils) stimulated uptake by around 55% (Fig. 3a). In the presence of compound FC671, an increase in uptake of about 60% was measured at 100 µM. The effect is even more pronounced at 50 nM since the increase amounts to + 95% (Fig. 3b). In FIGS. 3a and 3b, the cells are seeded in 9.6 cm 2 plates then incubated for 20 minutes with the compounds FC670 and FC671 or with insulin (positive control) then 2-eH] deoxy-D-glucose is added to the medium as described in the materials and methods chapter. Glucose uptake is measured by the incorporation of 2-eH] deoxy-D-glucose.

(*: p <0.05; ***: p <0.005).

<Desc / Clms Page number 25>

BIBLIOGRAPHICAL REFERENCES Bogdanowicz et al. (2001) Med / Sci 17, 577-585; Bogdanowicz et al. (1996) Cell. Signal. 8, 503-509; Bogdanowicz et al. (2000) Mol. Cell. Biochem. 208, 143-150; Frick et al. (1998) Biochemistry 37, 13421-13436 G. E. Keck, T. T. Wager, J. Org. Chem. 61 (1996) 8366-8367; Lamer et al (1988) Biochem. Biophys. Res. Comm. 151, 1416-1426; Saltiel et al. (1986) Proc. Nat. Acad. Sci. 83.5793-5797; Varela-Nieto et al. (1996) Comp. Biochem. Physiol.

115B, 223-241; W. Kinzy, R. R. Schmidt, Liebigs Ann. Chem. (1985), 1537-154 Biochemistry, 1998, Structure-Activity relationship of synthetic phosphoinositolglycans mimicking metabolic insulin action, vol 37, 38, 13421-13436 Remington's Pharmaceutical Sciences, 16th edition, Oslo, A. (ed), 1980;

Claims (14)

 CLAIMS 1. Compound of formula A

 R3 RI R6 - \. -0, R2 YXm, o O T Po R2 "\ vr \ R2 pus in which: ho 0 RI is selected from the group consisting of OH, an oligosaccharide, a polysaccharide, and R2 = R3 = OH; o Or at least one of the groups RI, R2, R3 is a group capable of modifying the lipophilicity of compound A, the other or the other two of these three groups being OH, And: - R4 is chosen from the group consisting of OH , NH2, a group capable of modifying the lipophilicity of compound A, and - R6 is H, OH or CH20H, and - X is chosen from 0, NH, S, CH2, and - R5 is chosen from OH, an oligosaccharide, a polysaccharide, a group capable of modifying the bioavailability of compound A, and its pharmaceutically acceptable salts. 2. Compound according to claim 1 characterized in that R1 = R2 = R3 = OH, and R4 is OH or NH2. 3. Compound according to claim 1 or 2 characterized in that R5 = OH, R6 = H. 4. Compound according to any one of claims 1 to 3 characterized in that the group or groups capable of modifying lipophilicity are chosen from a) an alkyl group, linear or branched, comprising less than 20 carbon atoms b) a group cycloalkyl comprising less than 10 carbon atoms c) a linear or branched alkenyl group comprising less than 20 carbon atoms <Desc / Clms Page number 27>  d) a cyclo-alkenyl group comprising less than 10 carbon atoms e) an aryl group comprising less than 20 carbon atoms f) an aralkyl group comprising less than 20 carbon atoms g) a heteroaryl group comprising 4 to 9 carbon atoms and at least one heteroatom chosen from oxygen, nitrogen, sulfur h) a heterocyclic group, comprising 2 to 9 carbon atoms and at least one heteroatom chosen from oxygen, sulfur and nitrogen. 5. Compound according to any one of claims 1 to 4 characterized in that X is in configuration a

 6. Compound according to any one of claims 1 to 4 characterized in that

 that X is in configuration ss

 7. Compound of formula I, OH Lo Ho HOw HO &commat; oS) R OH in which: \ / - X is chosen from 0, S, N uo "o - R7 is a hexose

 - R8 is chosen from OH, NH2 <Desc / Clms Page number 28>

 8. Compound of formula il, OH R7 0 HO \ /% OH D in which: HO o

 - X is chosen from 0, S, N - R7 is a hexose - R8 is chosen from OH, Nix 9. Compound according to any one of claims 1 to 8, as a medicament. 10. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to any one of claims 1 to 9, and a pharmaceutically acceptable vehicle. 11. A compound according to claim 6 or 8 for the treatment of diseases due to a deficient glucose metabolism. 12. Use of a compound according to claim 11 for the preparation of a medicament against disorders due to a deficient glucose metabolism. 13. A compound according to claim 5 or 7 for the treatment of diseases associated with excessive cell proliferation, in particular cancer, psoriasis, rheumatoid pannus. 14. Use of a compound according to claim 13 for the preparation of a medicament against diseases associated with excessive cell proliferation, in particular cancer, psoriasis, rheumatoid pannus.